$AGIO
AGIOS PHARMACEUTICALS, INC.

2013 Q4 Form 10-Q Financial Statement

#000119312513433119 Filed on November 07, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q4
Revenue $6.744M $6.268M $6.282M
YoY Change 7.35% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.710M $2.530M $1.550M
YoY Change 139.35% 60.13%
% of Gross Profit
Research & Development $15.28M $14.80M $11.23M
YoY Change 36.06% 51.08%
% of Gross Profit
Depreciation & Amortization $300.0K $400.0K $300.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $18.99M $17.34M $12.78M
YoY Change 48.59% 52.37%
Operating Profit -$12.24M -$11.07M -$6.498M
YoY Change 88.4% 116.61%
Interest Expense $30.00K $10.00K $10.00K
YoY Change 200.0% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.21M -$11.06M -$6.490M
YoY Change 88.14% 116.91%
Income Tax $170.0K $121.0K -$1.180M
% Of Pretax Income
Net Earnings -$12.38M -$11.18M -$5.313M
YoY Change 133.05% 140.62%
Net Earnings / Revenue -183.6% -178.32% -84.57%
Basic Earnings Per Share -$0.52
Diluted Earnings Per Share -$395.1K -$0.52 -$1.492M
COMMON SHARES
Basic Shares Outstanding 31.17M shares 22.74M shares
Diluted Shares Outstanding 22.74M shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $166.8M $195.0M $128.0M
YoY Change 30.31%
Cash & Equivalents $71.56M $106.0M $91.30M
Short-Term Investments $95.21M $88.90M $36.68M
Other Short-Term Assets $2.500M $3.800M $2.100M
YoY Change 19.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $169.7M $198.8M $130.1M
YoY Change 30.43%
LONG-TERM ASSETS
Property, Plant & Equipment $3.758M $3.551M $3.565M
YoY Change 5.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $27.10M $13.40M
YoY Change
Other Assets $4.000K $11.00K $22.00K
YoY Change -81.82%
Total Long-Term Assets $31.46M $20.25M $6.864M
YoY Change 358.3%
TOTAL ASSETS
Total Short-Term Assets $169.7M $198.8M $130.1M
Total Long-Term Assets $31.46M $20.25M $6.864M
Total Assets $201.2M $219.1M $137.0M
YoY Change 46.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.678M $2.140M $3.308M
YoY Change 11.19%
Accrued Expenses $6.586M $4.764M $1.708M
YoY Change 285.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $36.93M $37.38M $35.11M
YoY Change 5.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.000K $262.0K $358.0K
YoY Change -98.32%
Total Long-Term Liabilities $6.000K $262.0K $358.0K
YoY Change -98.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.93M $37.38M $35.11M
Total Long-Term Liabilities $6.000K $262.0K $358.0K
Total Liabilities $36.94M $37.64M $35.47M
YoY Change 4.13%
SHAREHOLDERS EQUITY
Retained Earnings -$113.4M -$101.1M -$74.04M
YoY Change 53.23%
Common Stock $244.9M $243.6M $2.015M
YoY Change 12054.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $131.5M $142.6M -$72.02M
YoY Change
Total Liabilities & Shareholders Equity $201.2M $219.1M $137.0M
YoY Change 46.86%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q4
OPERATING ACTIVITIES
Net Income -$12.38M -$11.18M -$5.313M
YoY Change 133.05% 140.62%
Depreciation, Depletion And Amortization $300.0K $400.0K $300.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$13.60M -$15.00M -$11.60M
YoY Change 17.24% 31.58%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$100.0K -$100.0K
YoY Change 100.0% -90.91%
Acquisitions
YoY Change
Other Investing Activities -$20.20M -$80.60M $19.80M
YoY Change -202.02% 16020.0%
Cash From Investing Activities -$20.40M -$80.70M $19.80M
YoY Change -203.03% 4647.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -400.0K 124.2M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -13.60M -15.00M -11.60M
Cash From Investing Activities -20.40M -80.70M 19.80M
Cash From Financing Activities -400.0K 124.2M 0.000
Net Change In Cash -34.40M 28.50M 8.200M
YoY Change -519.51% -317.56%
FREE CASH FLOW
Cash From Operating Activities -$13.60M -$15.00M -$11.60M
Capital Expenditures -$200.0K -$100.0K -$100.0K
Free Cash Flow -$13.40M -$14.90M -$11.50M
YoY Change 16.52% 44.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31171169 shares
CY2012Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2012Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83035000
CY2012Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2012Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31074168 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31074168 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4764000
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
426000
CY2013Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2140000
CY2013Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1492000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
37377000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
25000
CY2013Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1450000
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
262000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
142595000
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
243601000
CY2013Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101062000
CY2013Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25072000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
31000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
219069000
CY2013Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
5257000
CY2013Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144000
CY2013Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
38835000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
198818000
CY2013Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
13412000
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
102332000
CY2013Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
571000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11000
CY2013Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
88945000
CY2013Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
2706000
CY2013Q3 us-gaap Assets
Assets
219069000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106011000
CY2013Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
5000000
CY2013Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
102357000
CY2013Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2616000
CY2013Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2013Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1246000
CY2013Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
6200000
CY2013Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3551000
CY2013Q3 agio Number Of Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months
NumberOfAvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonths
26 Securities
CY2013Q3 agio Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
30000
CY2013Q3 agio Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
5000
CY2013Q3 agio Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
1396000
CY2013Q3 agio Number Of Individual Securities In Significant Unrealized Loss Position
NumberOfIndividualSecuritiesInSignificantUnrealizedLossPosition
0 Securities
CY2013Q3 agio Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event
PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent
22500000
CY2013Q3 agio One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program
OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram
25000000
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10700000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117661000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3616101 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3616101 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
78300000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1708000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
65000
CY2012Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3308000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
109000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35113000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-72024000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1124000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
358000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2012000
CY2012Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-74037000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25072000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137008000
CY2012Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4875000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
150000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
57639000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
130144000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
36681000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
571000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22000
CY2012Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
36679000
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
2706000
CY2012Q4 us-gaap Assets
Assets
137008000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91297000
CY2012Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
36679000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
922000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
1246000
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
13700000
CY2012Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3565000
CY2012Q4 agio Number Of Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months
NumberOfAvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonths
30 Securities
CY2012Q4 agio Availableforsale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableforsaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
2000
CY2012Q4 agio Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
410000
CY2012Q4 agio Number Of Individual Securities In Significant Unrealized Loss Position
NumberOfIndividualSecuritiesInSignificantUnrealizedLossPosition
0 Securities
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0123 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9260 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M10D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10111735 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42783000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.26
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3942500 shares
us-gaap Revenues
Revenues
18804000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1684000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26998000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26615000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
119498000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22863000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
121200000
us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26641000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Net Income Loss
NetIncomeLoss
-27025000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
75764000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-81000
us-gaap Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Amount
RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
124300000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1075000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
27000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2480000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6222000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
124304000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
115923000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-18804000
us-gaap Share Based Compensation
ShareBasedCompensation
1865000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
14714000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
382000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1178000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66807000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39223000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
410000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
53766000
us-gaap Depreciation
Depreciation
1100000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1865000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
410000
us-gaap Operating Expenses
OperatingExpenses
45445000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-4162000
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
410000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
410000
agio Estimated Performance Period Of Agreement
EstimatedPerformancePeriodOfAgreement
P6Y
agio Initial Public Offering Cost Incurred During Noncash Or Partial Noncash Transaction
InitialPublicOfferingCostIncurredDuringNoncashOrPartialNoncashTransaction
474000
agio Collaboration Revenue
CollaborationRevenue
18804000
agio Number Of Vendors Selling Similar Competitive Products
NumberOfVendorsSellingSimilarCompetitiveProducts
0 Vendor
agio Number Of Licensed Programs Type Under Collaboration Agreements
NumberOfLicensedProgramsTypeUnderCollaborationAgreements
3 Licensed_Program
agio Period Considered For Agreement Termination Notice
PeriodConsideredForAgreementTerminationNotice
P90D
agio Number Of Development Candidates Nominated By Joint Research Committee
NumberOfDevelopmentCandidatesNominatedByJointResearchCommittee
2 Candidate
agio Proceeds From Issuance Of Initial Public Offering And Private Placement
ProceedsFromIssuanceOfInitialPublicOfferingAndPrivatePlacement
124204000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0112 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9865 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M13D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3348372 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37919000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23141565 shares
us-gaap Revenues
Revenues
18824000
us-gaap Depreciation
Depreciation
856000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
460000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14813000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16437000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
71110000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9396000
us-gaap Income Taxes Paid
IncomeTaxesPaid
3549000
us-gaap Investment Income Interest
InvestmentIncomeInterest
61000
us-gaap Revenue From Grants
RevenueFromGrants
20000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16498000
us-gaap Net Income Loss
NetIncomeLoss
-14789000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-232000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1449000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
404000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5510000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
4789000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-18804000
us-gaap Share Based Compensation
ShareBasedCompensation
359000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-34626000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-9925000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-581000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
4789000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3205000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
359000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29812000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
4789000
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-6437000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-452000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-6437000
us-gaap Operating Expenses
OperatingExpenses
35322000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-5393000
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
370000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1648000
agio Collaboration Revenue
CollaborationRevenue
18804000
agio Reduction In Income Tax Liability Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxLiabilityDueToCarrybackOfDeferredTaxAssets
500000
agio Reduction In Income Tax Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxDueToCarrybackOfDeferredTaxAssets
1600000
CY2013Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.75
CY2013Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
19731564 shares
CY2010Q2 agio Expiration Extension Period Under Collaboration Agreement
ExpirationExtensionPeriodUnderCollaborationAgreement
P2Y
CY2010Q2 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2014-04
CY2011Q4 agio Initial Agreement Period
InitialAgreementPeriod
P3Y
CY2011Q4 agio Date Of Extension Of Discovery Phase
DateOfExtensionOfDiscoveryPhase
2016-04
CY2011Q4 agio Extended Agreement Period
ExtendedAgreementPeriod
P4Y
CY2011Q4 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0082 pure
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8944 pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M21D
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3439105 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23141565 shares
CY2012Q3 us-gaap Revenues
Revenues
6268000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4644000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5097000
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2847000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5110000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-4645000
CY2012Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1580000
CY2012Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1472000
CY2012Q3 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2012Q3 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
1472000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9798000
CY2012Q3 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2012Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1924000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
170000
CY2012Q3 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-1924000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
11378000
CY2012Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-1798000
CY2012Q3 agio Collaboration Revenue
CollaborationRevenue
6268000
CY2012Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
168000
CY2012Q3 agio Reduction In Income Tax Liability Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxLiabilityDueToCarrybackOfDeferredTaxAssets
500000
CY2012Q3 agio Reduction In Income Tax Due To Carryback Of Deferred Tax Assets
ReductionInIncomeTaxDueToCarrybackOfDeferredTaxAssets
1600000
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0173 pure
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9425 pure
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M2D
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22744486 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3942500 shares
CY2013Q3 us-gaap Revenues
Revenues
6268000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11147000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11056000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10610000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11069000
CY2013Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-11177000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2534000
CY2013Q3 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14803000
CY2013Q3 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2013Q3 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
121000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1112000
CY2013Q3 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
121000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
17337000
CY2013Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
-567000
CY2013Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
121000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
121000
CY2013Q3 agio Collaboration Revenue
CollaborationRevenue
6268000

Files In Submission

Name View Source Status
0001193125-13-433119-index-headers.html Edgar Link pending
0001193125-13-433119-index.html Edgar Link pending
0001193125-13-433119.txt Edgar Link pending
0001193125-13-433119-xbrl.zip Edgar Link pending
agio-20130930.xml Edgar Link completed
agio-20130930.xsd Edgar Link pending
agio-20130930_cal.xml Edgar Link unprocessable
agio-20130930_def.xml Edgar Link unprocessable
agio-20130930_lab.xml Edgar Link unprocessable
agio-20130930_pre.xml Edgar Link unprocessable
d601988d10q.htm Edgar Link pending
d601988dex311.htm Edgar Link pending
d601988dex312.htm Edgar Link pending
d601988dex321.htm Edgar Link pending
d601988dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending